Methods and Compounds for Restoring Mutant p53 Function
Summary
USPTO published patent application US20260098032A1 disclosing compounds that bind mutant p53 proteins and restore their wild-type DNA-binding and tumor-suppressor activity. The compounds are directed at reducing cancer progression in tumors harboring p53 mutations. The application was filed on 2025-05-15 under CPC classes C07D 405/14 and related organic chemistry subclasses.
What changed
USPTO published a patent application (US20260098032A1) disclosing heterocyclic compounds and methods for restoring wild-type function to mutant p53 tumor suppressor proteins. The disclosed compounds bind mutant p53, enabling the protein to re-engage DNA and activate downstream tumor suppression effectors, thereby reducing cancer progression in p53-mutated tumors.
For pharmaceutical manufacturers and biotech companies developing oncology therapeutics, this patent creates potential freedom-to-operate considerations for any p53-targeting drug discovery programs. Researchers and developers in the cancer therapeutics space should conduct landscape analyses to assess whether their compounds fall within the scope of these claims or would constitute non-infringing alternatives.
What to do next
- Review patent claims for freedom-to-operate analysis
- Monitor for issued patent and any continuation applications
- Assess therapeutic development pipeline impact on p53-targeted oncology programs
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
Application US20260098032A1 Kind: A1 Apr 09, 2026
Inventors
Binh VU, Romyr DOMINIQUE, Hongju LI, Bruce FAHR, Andrew GOOD
Abstract
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
CPC Classifications
C07D 405/14 C07D 209/14 C07D 401/12 C07D 401/14 C07D 403/06 C07D 403/12 C07D 405/12 C07D 409/12 C07D 409/14 C07D 417/14 C07D 471/04 C07D 471/08 C07D 491/107 C07F 7/0812 C07H 15/26
Filing Date
2025-05-15
Application No.
19209328
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.